MSMylène Sebagh

Mylène Sebagh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mylène Sebagh has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rare genetic heterogeneity within single tumor discovered for the first time in colorectal liver metastases after liver resection

    by Mylène Sebagh, Nelly Bosselut, Alexandre Dos Santos, Marc-Antoine Allard, Aldrick Ruiz, Raphaël Saffroy, Daniel Cherqui, Eric Vibert, Denis Castaing, René Adam, et al.

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Mylène Sebagh1, 2, 3, 4, Nelly Bosselut2, 3, 4, 5, Alexandre Dos Santos2, 3, 4, Marc-Antoine Allard2, 3, 4, 6, 7, Aldrick Ruiz6, 8, Raphaël Saffroy2, 3, 4, 5, Daniel Cherqui2, 3, 4, 6, Eric Vibert2, 3, 4, 6, Denis Castaing2, 3, 4, 6, René Adam3, 4, 6, 7, Antonio Sa Cunha2, 3, 4, 6 and Antoinette Lemoine2, 3, 4, 5 1AP-HP Hôpital Paul Brousse, Laboratoire d’Anatomie Pathologique, Villejuif, France 2Inserm, Unité 1193, Université Paris-Saclay, Villejuif, France 3Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, Villejuif, France 4DHU Hepatinov, Villejuif, France 5AP-HP Hôpital Paul Brousse, Département d’Oncogénétique, Villejuif, France 6AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, France 7Inserm, Unité 935, Université Paris-Saclay, Villejuif, France 8University Medical Center Utrecht, Department of Surgery, Utrecht, The Netherlands Correspondence to: Mylène Sebagh, email: mylene.sebagh@pbr.aphp.fr Keywords: colorectal liver metastases; intratumoral genetic heterogeneity; pathological response; mutations Received: June 05, 2017 Accepted: March 21, 2018 Published: April 24, 2018 ABSTRACT Effective individualized treatment of patients with colorectal liver metastases (CLM) requires tumor genotyping, usually based on the analysis of one single sample per patient. Therapy failure may partially be explained by sampling errors and/or intratumoral genetic heterogeneity. We aimed to demonstrate intratumoral genetic heterogeneity in CLM and enable pathologists to select tumor tissue for genotyping. All the tumors of 86 patients who underwent liver resection for a single CLM were reviewed. Of the 86 patients, 66 patients received chemotherapy and 20 patients did not receive chemotherapy before liver resection. All the tumor areas sampled were analyzed for KRAS, BRAF, PIK3CA, and NRAS mutations. The mutational status was tested in 74 cases, 7 cases had no tumoral cells due to complete responses and 5 blocks were unavailable. Of the 59/74 CLM with > 1 sample, 56 showed the same mutational status between the samples. The remaining 3 cases (5% of all cases) showed genetic heterogeneity for KRAS in 2 and BRAF in 1 patient. Genetic heterogeneity correlated with lower rate of viable tumor cells (p=0.009) and higher rate of mucin pools (p=0.013). We demonstrate for the first time the existence of genetic intratumoral heterogeneity in 5% of CLM. In routine practice, this low incidence does not require the genotyping of additional tumor samples. The correlation between the genetic heterogeneity and some histological components of the CLM should be verified by further in situ mutation assay.


  • Open Access

    Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy

    by Mylène Sebagh, Marc-Antoine Allard, Nelly Bosselut, Myriam Dao, Eric Vibert, Maïté Lewin, Antoinette Lemoine, Daniel Cherqui, René Adam, Antonio Sa Cunha

    Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy


  • Open Access

    Idiopathic Post Liver-Transplant Hepatitis Remains Obscure with Respect to Its Etiology and Relationship with Immunosuppressiona

    by Myl鑞e Sebagh, Ap-Hp Hôpital Paul-Brousse Laboratoire D’anatomie Pathologique, Audrey Coilly, St閜hanie Ha飉-Boukobzsa, Marc-Antoine Allard, Eric Ballot, Antonio Sa Cunha, Bruno Roche, Faouzi Saliba, Anne-Marie Roque-Afonso, et al.

    Idiopathic Post Liver-Transplant Hepatitis Remains Obscure with Respect to Its Etiology and Relationship with Immunosuppressiona


  • Open Access

    A proposed new method for assessing the pathological response to chemotherapy in resected colorectal liver metastases

    by M Sebagh, M-A Allard, A S Cunha, A Ruiz, R Araujo, A Lemoine, B Paule, V Delvart, D Cherqui, E Vibert, et al.

    Pathological response (PR) to preoperative chemotherapy for colorectal liver metastases (CLM) is recognised as a prognostic factor of outcome. However, the optimal system to assess this parameter is still debated. This study focuses on current methods and proposes a possibly better method for assessing PR. Among 223 patients resected for CLM between 2004 and 2011, after more than three cycles of chemotherapy, the percentage of tumour cells, necrosis and fibrosis, and the tumour regression grade were assessed for each of 802 nodules. Pathological response was evaluated according to validated methods and their combinations. A new method combined the percentage of tumour cells and the size of all nodules as follows: , where n is each separate nodule, % is the percentage of remaining tumour cells within nodule n (%) and s is the size of nodule n (cm).The prognostic value of each method was calculated. After a median follow-up of 47 months (3-106), the cumulative 5-year overall survival rate after liver resection was 59%. The proposed method categorised as follows: 0 residual tumour; 0.1-6-cm residual tumour; >6-cm residual tumour, and necrosis rate >50% stratified prognosis (P=0.0027; P=0.02), while the other methods did not. At multivariate analysis, our method remained an independent predictor of outcome (P=0.001). Combining the percentage of tumour cells multiplied by the size of each separate tumour seems to be a better method for assessing PR. External validation is required.


  • 843 Immunoglobulin G4 Plasma Cell Bias in de novo Autoimmune Hepatitis Patients

    by Marcela Castillo-Rama, Eizaburo Sasatomi, Mylene Sebagh, Parmjeet Randhawa, Kumiko Isse, Abhinav Humar, Anthony J. Demetris

  • Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients

    by Mylène Sebagh, Didier Samuel, Teresa Maria Antonini, Audrey Coilly, Davide Degli Esposti, Bruno Roche, Vincent Karam, Alexandre Dos Santos, Jean-Charles Duclos-Vallée, Anne-Marie Roque-Afonso, et al.


  • Open Access

    Significance of Isolated Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome After Liver Transplantation

    by Mylène Sebagh, Daniel Azoulay, Bruno Roche, Emir Hoti, Vincent Karam, Elina Teicher, Laurence Bonhomme-Faivre, Faouzi Saliba, Jean-Charles Duclos-Vallée, Didier Samuel

    After liver transplantation (LT), hepatic veno-occlusive disease (VOD), which is also known as sinusoidal obstruction syndrome (SOS), has been reported initially in relation to azathioprine use and subsequently in relation to acute rejection (AR). Isolated veno-occlusive disease (iVOD)/SOS raises some questions about its significance and especially its treatment. From the post-LT biopsy samples of 1364 patients (2000-2008), 31 patients with index biopsy samples showing VOD/SOS (2.3%) were identified. After a review of the index biopsy samples and previous biopsy samples, those patients not exposed to azathioprine therapy were subdivided into 2 groups according to the absence or presence of AR. Fifteen of the 31 patients had no previous evidence of AR, whereas 16 experienced episodes of AR (before or concurrently with VOD). The 2 groups were similar in terms of demographic and clinical data and the range of histological centrilobular changes. AR episodes were characterized by an endothelial predilection. iVOD/SOS occurred later than acute rejection–related veno-occlusive disease (AR-VOD)/SOS (mean times of 65 and 4.4 months, respectively, P = 0.0098). There was a tendency for iVOD/SOS to progress less frequently to chronic rejection in comparison with AR-VOD/SOS (3/15 versus 9/15, P = 0.06). The histological resolution of iVOD/SOS was significantly more frequent in patients who benefited from increased immunosuppression in comparison with those who did not (5/7 versus 2/8, P = 0.05). When the groups were considered together, the same result was obtained (14/18 versus 4/12, P = 0.024). In conclusion, despite a constant overall prevalence of VOD/SOS, the proportion of iVOD/SOS has increased. The histological resolution of iVOD/SOS after increase in immunosuppression suggests an immune-mediated origin. Better optimization of immunosuppression may be a curative treatment. Liver Transpl 17:798-808, 2011. © 2011 AASLD.